Myasthenia Gravis: Is Your Muscle Weakness Actually a Neurological Problem?

Myasthenia gravis is an autoimmune condition where the body produces antibodies that attack acetylcholine receptors at the neuromuscular junction, the point where nerve signals cross over to trigger muscle contraction. When those receptors are blocked or destroyed, the electrical signal from the nerve reaches a muscle that can no longer respond properly, producing the characteristic weakness that worsens with activity and improves with rest.

According to Dr. Guruprasad Hosurkar, a leading neurologist in Bangalore,
“Myasthenia gravis is one of the most underdiagnosed neuromuscular conditions because the weakness is fatigable – it comes and goes, gets worse as the day progresses, and often starts in the eyelids or eye muscles before spreading. Patients spend months seeing ophthalmologists or orthopaedic surgeons before someone recognises the neurological pattern.”

The hallmark of myasthenia gravis is fatigable weakness – muscle strength that deteriorates with repeated use and recovers partially with rest. This fluctuating pattern is what separates it from structural muscle disease and makes early recognition so clinically important.

• Ocular symptoms are the most common first sign: Drooping of one or both eyelids (ptosis) and double vision (diplopia) from eye muscle weakness affect over 50% of patients at onset, and in purely ocular myasthenia gravis, symptoms stay confined to the eyes throughout.
• Bulbar weakness affects swallowing and speech: Weakness of the throat and tongue muscles causes difficulty chewing, nasal speech, and choking on liquids – symptoms that worsen toward the end of a meal and improve after rest.
• Limb weakness follows a proximal pattern: Arm and leg weakness in myasthenia gravis affects muscles closer to the body first, making tasks like climbing stairs, lifting arms overhead, or rising from a chair progressively harder through the day.
• Myasthenic crisis is a life-threatening escalation: Respiratory muscle involvement can progress rapidly to breathing failure, triggered by infection, surgery, or certain medications, requiring emergency ventilatory support and immediate immunotherapy. Unlike other neuromuscular conditions such as Guillain-Barre syndrome, myasthenic crisis is often predictable and preventable with good disease management.

The fatigable, fluctuating nature of the weakness is the single most important diagnostic clue, and missing it is how patients end up with the wrong diagnosis for months.

Accurate diagnosis requires a combination of blood tests, nerve studies, and imaging rather than any single test. Treatment is long-term and layered, targeting both symptom control and the underlying immune mechanism driving the condition.

• Antibody testing confirms the diagnosis in most cases: AChR antibodies are positive in roughly 85% of generalised myasthenia gravis patients, while MuSK antibodies account for a significant proportion of the seronegative cases – testing for both is standard in any Guillain-Barré Syndrome Treatment workup.
• Electrophysiology provides objective confirmation: Repetitive nerve stimulation showing a decremental response and single-fibre EMG detecting abnormal jitter are the two key electrophysiological tests that confirm neuromuscular junction dysfunction when antibody tests are inconclusive.
• CT chest is mandatory to exclude thymoma: Around 10 to 15% of myasthenia gravis patients have a thymoma, and thymectomy in eligible patients – including those without thymoma but under 65 – produces meaningful long-term remission rates that medication alone cannot achieve.
• Treatment is staged from symptomatic to immunosuppressive: Pyridostigmine improves symptoms by slowing acetylcholine breakdown at the junction, while prednisolone and steroid-sparing agents like azathioprine or mycophenolate address the underlying immune dysregulation for sustained disease control.

Each of these steps builds on the one before it, which is why myasthenia gravis management works best when it is coordinated by a neurologist who handles the full diagnostic and treatment pathway rather than individual components in isolation.

Dr. Guruprasad Hosurkar practises at KIMS Hospital, Mahadevapura, with specialist experience in neuromuscular and autoimmune neurological conditions including myasthenia gravis. His approach covers the full diagnostic workup from antibody testing and electrophysiology through to thymoma screening, alongside long-term immunosuppressive management tailored to each patient’s disease pattern and response. Patients with fatigable weakness that has gone undiagnosed or misdiagnosed get a structured re-evaluation that starts with the neuromuscular junction, not the muscles themselves.

References

1. 1. 1. 1. 1. 1. A practical approach to managing patients with myasthenia gravis
               2. Myasthenia gravis and acetylcholine receptor antibodies